Are CAR T cells the answer to myasthenia gravis therapy?

Myasthenia gravis is a chronic autoimmune disorder that is characterised by fluctuating muscle weakness. In people with myasthenia gravis, pathogenic IgG autoantibodies target proteins in the postsynaptic neuromuscular junction, such as the acetylcholine receptor (AChR) or MuSK, thereby impairing the function of skeletal muscles.1 Myasthenic crisis, a life-threatening manifestation of the disease that involves respiratory failure, affects about 15% of individuals with myasthenia gravis, of whom 12–18% die.